(3-chloro-phenoxy)-acetic acid [1-pyridin-4-yl-meth-(E)-ylidene]-hydrazide | 919523-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (3-chloro-phenoxy)-acetic acid [1-pyridin-4-yl-meth-(E)-ylidene]-hydrazide
• 英文别名: 2-(3-chlorophenoxy)-N-[(E)-pyridin-4-ylmethylideneamino]acetamide
• CAS: 919523-43-6
• 化学式: C₁₄H₁₂ClN₃O₂
• 分子量: 289.721
• InChiKey: LWZAAJNMFIEBCJ-RQZCQDPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Hydrazide compounds
  申请人：deLong A. Mitchell

  公开号：US20070135499A1

  公开（公告）日：2007-06-14

  Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions controlled or influenced by GPCRs are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  提供了具有GPCR脱敏抑制活性的肼基化合物，可用于影响、抑制或减少G蛋白受体激酶的作用。还提供了包括治疗有效量肼基化合物和药用可接受载体的药物组合物。还提供了使用这些化合物和/或组合物影响由GPCR控制或影响的疾病状态或病况的各种方法。还提供了使用这些化合物和/或组合物影响疾病状态或病况，如癌症、骨质疏松症和青光眼等的各种方法。
• [EN] HYDRAZIDE COMPOUNDS<br/>[FR] COMPOSES D'HYDRAZIDE
  申请人：AERIE PHARMACEUTICALS INC

  公开号：WO2007008942A2

  公开（公告）日：2007-01-18

  [EN] Hydrazide compounds with GPCR desensitization inhibitory activity are provided that may be used to influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the hydrazide compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions controlled or influenced by GPCRs are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
  [FR] La présente invention concerne des composés d'hydrazide ayant une activité d'inhibition de désensibilitation de GPCR et pouvant être utilisés pour agir sur, inhiber ou réduire l'action de la kinase de récepteur de protéine G. L'invention a également pour objet des compositions pharmaceutiques comprenant des quantités efficaces d'un point de vue thérapeutique des composés d'hydrazide et des excipients acceptables d'un point de vue pharmaceutique. L'invention concerne aussi différents procédés faisant intervenir les composés et/ou les compositions, pour agir sur des maladies ou des états pathologiques contrôlés ou influencés par GPCR, ainsi que différents procédés faisant intervenir les composés et/ou les compositions pour agir sur des maladies ou des états pathologiques tels que le cancer, l'ostéoporose et le glaucome.